Member Article

Perfectus Biomed win £100k from North West Fund

Funding has been secured by a microbiological testing company based in Sci-Tech Daresbury through The North West Fund (TNWF) for Biomedical.

Perfectus Biomed, which specialises in antimicrobial and anti-biofilm agents and devices, has raised a £100,000 investment, which was provided evenly between TNWF and venture capital firm, Midven.

The funding will be used to expand the business’ research team, which it said will help them meet growing demand for testing.

Plans to implement a marketing strategy across the UK and Europe will also be supported through the funding, while the business hopes to invest in capital assets to improve their service and develop their management systems.

Dr Samantha Westgate, business and scientific director of Perfectus Biomed, said: “We are delighted to receive this investment.

“It will support the growth and development of Perfectus Biomed, enabling us to increase employee numbers and drive our exciting expansion into new sectors.”

TNWF for Biomedical is managed by SPARK Impact, and this investment marks the funds 57th fund distribution to date, while Perfectus Biomed is the 38th company to receive funding.

Dr Penny Attridge, senior investment director at SPARK Impact and manager of TNWF for Biomedical, said: “Perfectus Biomed has developed a novel research based approach to microbiological testing and we’re pleased to support the firm in its growth plans.

“Its work supports key medical sectors and we believe it to be a huge asset to SPARK’s biomedical portfolio.”

Director of Midven and investment director of the Rainbow Seed Fund, Dr Andrew Muir, added: “There are very few companies that provide the services of which Perfectus can be justifiably proud, so there is considerable potential for growth.

“The importance of biofilm testing is being increasingly recognised across the consumer and medical device sectors and Perfectus is uniquely poised to take advantage of this.

“They are precisely the sort of organisation which can benefit from venture capital funding as they look to grow their laboratory as well as the sales resource, both of which are key in helping move the company on to the next stage.”

This was posted in Bdaily's Members' News section by Miranda Dobson .